Shots:

• EMA has granted PRIME designation for iptacopan (LNP023) in C3 glomerulopathy (C3G). PRIME designation enhancing the development of medicine targeting unmet medical need. Results of P-II interim analysis for iptacopan in C3G will be presented at ASN 2020
• Additionally- the company is investigating iptacopan in P-III study in PNH patients with residual anemia despite treatment with anti-C5 Ab therapy- planned to initiate in Dec’2020. The P-II data in PNH presented at EBMT
• Iptacopan is an oral- small-molecule- reversible inhibitor of factor B and has received FDA’s & EMA’s ODD in C3G- based on the preliminary data from the ph2 trial

Ref: Novartis | Image: Novartis